Astellas Pharma US, Inc.
3-11 Nihonbashi-Honcho 2-chome
About Astellas Pharma US, Inc.
527 articles with Astellas Pharma US, Inc.
9/24/2018Here's a look at who's making moves in the biotech and pharma world this week.
Bill and Giuliana Rancic to Lend Expertise, Passion and Personal Cancer Experience to Inspire Fellow Entrepreneurs
Additional marketing award received for Best Video/TV Campaign
More than 800 Astellas Employees Volunteer for 16 Community Organizations as Part of Ninth Annual Changing Tomorrow Day
More than 800 Astellas employees joined together across four countries to help their communities and volunteer at 16 local nonprofit organizations.
CancerLinQ LLC announced today that Integra Connect’s EHR Solution for Oncology has been recognized as the first CancerLinQ® Certified Electronic Health Record (EHR) System.
Astellas today announced that Rodrigo Fernandez has been promoted to vice president, Latin America, based in Northbrook and reporting to Percival Barretto-Ko, president, Astellas Americas.
Shontelle was formerly the senior vice president, Medical Affairs for the Americas.
Pfizer and Astellas Pharma announced they have amended the protocols for two Phase III clinical trials, ARCHES and EMBARK, to evaluate Xtandi (enzalutamide) in hormone-sensitive prostate cancer (HSPC). Both trials will wrap sooner than planned as a result.
Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer
Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced amendments to the protocols for two registrational Phase 3 trials, ARCHES and EMBARK, designed to evaluate the safety and efficacy of XTANDI® (enzalutamide) in men with hormone-sensitive prostate cancer (HSPC).
Japan-based Astellas plunked down nearly $109 million to snap up privately-held gene therapy company Quethera Limited and its novel treatments for glaucoma and other ocular disorders.
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule compound technologies, today announced that the Board of Directors has appointed Jim Scully as interim chief executive officer.
Astellas announced that Nahrin Marino, Deputy General Counsel, Legal, will be recognized as one of the most inspirational people in the life sciences industry by the Healthcare Businesswomen's Association (HBA).
The Illinois Employer Support of the Guard and Reserve (ESGR) Awards program has selected Astellas for its highest honor - the Pro Patria Award - as the state's top large employer over the past year.
By exercising the option right to acquire Mitobridge, Astellas paid $225M to acquire 100% of the equity in Mitobridge.
Astellas Receives Orphan Designation from the European Commission for Gilteritinib for the Treatment of Acute Myeloid Leukaemia
The decision follows a positive recommendation for Orphan Designation from the EMA COMP.
The drug did not meet its primary or secondary endpoints in the Phase 3 HELIOS clinical trial.
ClearPath Development Company Launches Third Collaboration Under Strategic Partnership With Astellas Pharma to Develop Staphylococcus Aureus Vaccine With Boston Children's Hospital
ClearPath announced today it has initiated a third research collaboration with Astellas Pharma to combat infections.
Astellas today announced two senior-level changes in its U.S. Commercial organization within the company's Health Systems business unit.
U.S. FDA Grants Fast Track Designation To Astellas For Development Of Gilteritinib In Relapsed Or Refractory Acute Myeloid Leukemia
Astellas And Seattle Genetics Initiate Pivotal Trial Of Enfortumab Vedotin For Patients With Locally Advanced Or Metastatic Urothelial Cancer